MedTrace Logo

Liposomal Bupivacaine vs Ropivacaine for TAPBs

NCT06430112 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-05-28

No results posted yet for this study

Summary

Few studies have compared the efficacy of ultrasound (US)-guided TAP blocks with Liposomal bupivacaine(LB) versus ropivacaine in reducing postoperative opioid usage in patients undergoing laparoscopic lower abdominal tumor Resection. Therefore, we are conducting this prospective, randomized controlled trial to compare the postoperative analgesic effects of LB and ropivacaine for TAP blocks among patients undergoing laparoscopic colorectal procedures.

Conditions

  • Abdominal Tumor
  • Postoperative Analgesia
  • Liposomal Bupivacaine
  • Ropivacaine

Interventions

DRUG

Liposomal Bupivacaine

After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).

DRUG

Ropivacaine

Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Jingdun Xie · Department of Anesthesiology,Sun Yat-Sen University Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2024-05-20
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06430112 on ClinicalTrials.gov